Phytosterols in Seaweeds: An Overview on Biosynthesis to Biomedical Applications

Soo-In Sohn 1,*, Periyasamy Rathinapriya 2,3,†, Sekaran Balaji 4,†, Devasahayam Jaya Balan 2,†, Thirukannamangai Krishnan Swetha 2,†, Ravindran Durgadevi 2,†, Selvaraj Alagulakshmi 2,†, Patchiappan Singaraj 4 and Subramani Pandian 1,†

1 Department of Agricultural Biotechnology, National Institute of Agricultural Sciences, Rural Development Administration, Jeonju 54874, Korea
2 Department of Biotechnology, Alagappa University, Karaikudi 630 003, India; rathina.priya25@gmail.com (P.R.); balanjaya38@gmail.com (D.J.B.); swethakrishnan02@gmail.com (T.K.S.); devdurgat66@gmail.com (R.D.); lakshmivinay317@gmail.com (S.A.)
3 Department of Biotechnology, Vidhyaa Giri College of Arts and Science, Karaikudi 630 003, India
4 Independent Researcher, Madurai 625 020, India; balajisekar91@yahoo.in (S.B.);

* These authors have contributed equally to this work.
† These authors have contributed equally to this work.

Abstract: Seaweed extracts are considered effective therapeutic alternatives to synthetic anticancer, antioxidant, and antimicrobial agents, owing to their availability, low cost, greater efficacy, eco-friendly nature. Since the bioactive constituents of seaweed, in particular, phytosterols, possess plenty of medicinal benefits over other conventional pharmaceutical agents, they have been extensively evaluated for many years. Fortunately, recent advances in phytosterol-based research have begun to unravel the evidence concerning these important processes and to endow the field with the understanding and identification of the potential contributions of seaweed-steroidal molecules that can be used as chemotherapeutic drugs. Despite the myriad of research interests in phytosterols, there is an immense need to fill the void with an up-to-date literature survey elucidating the biosynthesis, pharmacological effects, and other biomedical applications. Hence, in the present review, we summarize studies dealing with several types of seaweed to provide a comprehensive overview of the structural determination of several phytosterol molecules, their properties, biosynthetic pathways, and mechanisms of action, along with their health benefits, which could significantly contribute to the development of novel drugs and functional foods.

Keywords: antioxidants; antimicrobials; β-sitosterol; functional foods; phytosterols; seaweeds

1. Introduction

Marine macroalgae (or seaweed) hold immense nutritional value and have constituted an important position in Asian diets since time immemorial. Traditionally, seaweeds viz., Undaria pinnatifida (wakame), Cladosiphono kawamuras (mozuku), Laminaria japonica (kombu) and Gelidium crinale (tengusa) are consumed as healthy foods in Japan [1]. Sargassum fusiforme, in addition to being one of the edible seaweeds consumed in Korea and China, holds an important position in traditional Chinese medicine due to its anti-atherosclerotic activity [2]. In recent times, the demands for seaweed in other parts of the world, such as North and South America, have also increased due to the migration of traditional seaweed consumers. Moreover, France has recently approved the human consumption of seaweed as condiments and vegetables, which further increases the value of seaweed in the global food market. Although seaweed has been consumed since prehistoric times, its commercial utilization in food, cosmetics, and pharmaceutical industries was recognized later [3]. Seaweed extracts are generally rich in natural growth hormones, nutrients, and...
trace minerals. Among several other compounds, the nutritional value of seaweed is mainly attributed to the presence of phytosterols. Phytosterols, as the name implies, are defined as fatty compounds produced by plants, and remarkably contribute as the major lipid constituent of biological membrane of plant cells. Although these plant steroids have similar chemical structures like cholesterol, the differentiation in C_{24} side chains makes them metabolically and functionally distinct from each other [4]. Like terrestrial plants, seaweeds as well, exhibit the diversified composition of phytosterol contents with a similar profile of health benefits and their prevalence in this phytoplankton is largely influenced by their evolutionary origin [5,6]. For instance, brown algae (phaeophyta) predominantly contain phytosterols such as fucosterol and brassicasterol, with a small proportion of plant cholesterol and therefore considered a promising source for phytosterols. In contrast, red algae (rhodophyta) contain cholesterol as their principal sterol content, with a minor quantity of phytosterols such as sitosterol, fucosterol, chalinasterol and desmosterol. On the other hand, green algae (chlorophyta) vary in their types of sterols, such as ergosterol, chondrillasterol, β-sitosterol, 28-isofucosterol, cholesterol and poriferasterol, depending on the species [7,8]. Furthermore, to date, there have been no studies found to demonstrate the obvious negative effects (in terms of toxicity) of phytosterols on humans. Accordingly, international agencies such as the Food and Drug Administration (FDA) and the European Union Scientific Committee (EUSC) have already approved phytosterols as safe to use [9]. Despite the myriad of research interest in phytosterols, there has been a lacuna in an up-to-date literature survey elucidating their biosynthesis, pharmacological effects and other biomedical applications. Therefore, the goal of this review is to provide an overview of the biosynthesis, extraction, and characterization of phytosterols in seaweed, as well as of their biological properties with biomedical applications, for effective seaweed utilization in the food and pharmaceutical industries.

2. Biosynthesis of Phytosterols

The sterol biosynthesis pathway is an important pathway of living organisms, exhibited by certain bacteria and all eukaryotes [10,11]. Recent discoveries have increased the complexity of this pathway, urging researchers to decipher it further in order to deepen perceptions of its activity. Phytosterol biosynthesis is a branch of sterol synthesis found in almost all plant species and it can be distinguished from the sterol biosynthesis pathway of all eukaryotic kingdoms, such as animals and fungi. Although seaweeds are known to be potential producers of phytosterols, not all species of seaweeds have evolved to do so. Only limited species, such as brown seaweed, have the ability to produce phytosterols such as fucosterol and saringosterol. These sterols have therapeutic implications, such as neurostimulatory effects, and thus have piqued the interest of the clinical community [12,13]. The paucity of investigation and the diversity of macroalgal species have obscured the identification of pathways responsible for phytosterol synthesis. Nevertheless, Calegario et al. [14] postulated that seaweeds may use the traditional pathways of plants for isoprene unit synthesis. As in plant species, the phytosterol biosynthesis in macroalgae can be stratified into three major segments: (i) the biosynthesis of isoprene, (ii) the condensation of isoprene into triterpenoids and their epoxidation and (iii) the biosynthesis of phytosterols [15]. In these sequential reactions, products of glycolysis are converted into hydrocarbons such as isoprene to triterpenoids and final end products of phytosterols [16].

2.1. Biosynthesis of Isoprene

Isoprene is the basic unit of all isoprenoids and terpenoids with a five-carbon functional group [17]. In a eukaryotic cell, the synthesis of isoprenes, namely isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) can be carried out through two unique pathways called mevalonate (MVA) and methylerythritol phosphate (MEP) pathways. All plant species can utilize both these pathways to generate the precursors of isoprenes. In contrast, green macroalgae are found to use the MEP pathway, as they lack the genes involved in the MVA pathway. However, red algae have the potency to
synthesize IPP and DMAPP through both these cytosolic- and plastid-relying mechanisms. It is postulated that during endosymbiosis, green algae could have lost machinery from the MVA pathway and evolved with most relying on the MEP pathway for all fundamental aspects of isoprenoid synthesis. Conversely, primary endosymbionts, such as plants and red algae, have retained both MVA and MEP pathways over their evolutions [18]. Most portions of the MVA and MEP pathways transpire in the cytoplasm and plastid, respectively. Interestingly, all the sequential events of the MEP pathway ensue in plastids; however, the genes involved in these processes are encoded by the nuclear genome [19,20]. Furthermore, the MEP pathway produces both IPP and DMAPP directly, whereas MVA produces only IPP that is followed by isomerization of IPP into DMAPP by IPP isomerase (IPPI). As green algae rely solely on the MEP pathway for isoprenoid synthesis, they have evolved to express chloroplast membranal antiporters to maintain a balanced flux of IPP/DMAPP between plastid and cytosol [21]. Though the MEP pathway produces both these precursors, the ratio of IPP: DMAPP generated through this event varies among plant species.

The MVA pathway comprises six enzymatic reactions, which commence with acetyl-CoA condensation by acetyl-coA C-acetyltransferase (ACCT), followed by synthesis of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) by HMG-CoA synthase (HMGS) with subsequent reduction by HMG reductase (HMGR) to form MVA as an intermediate. MVA is then pyrophosphorylated and decarboxylated in subsequent steps by mevalonic acid (MK), phosphomevalonate (PMK) kinases and mevalonate-5-diphosphate decarboxylase (MPDC), respectively, to form the final isoprene unit, IPP. In the MEP pathway, the final product pyruvate, and intermediate- glyceraldehyde-3-phosphate (G3P), of glycolysis are converted into isoprene via seven successive steps. Pyruvate and G3P are condensed together to produce 1-deoxy-D-xylulose 5-phosphate (DXP) by DXP synthase (DXS), followed by reduction, cytidylation, phosphorylation, decytidylation and final reduction by DXP-reductoisomerase (DXR), 2-C-methyl-d-erythritol 4-phosphate cytidylyltransferase (MCT), 4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol kinase (CMK), 2-C-methyl- D-erythritol 2,4-cyclodiphosphate synthase (MDS), 4-hydroxy-3-methylbut-2-enyldiphosphate (HMBPP) synthase (HDS) and HMBPP reductase (HDR), respectively, to generate the end isoprene products IPP and DMAPP (Figure 1A).

2.2. Condensation of Isoprene into Triterpenoids and Their Epoxidation

Isoprene, with a five-carbon atom, condenses together to generate monoterpenes (C10), sesquiterpenes (C15), diterpenes (C20), and triterpenes (C30). Triterpenes serve as precursors for phytosterol synthesis. Isoprene from the MEP pathway catalyzes the synthesis of monoterpenes, diterpenes, chlorophyll, carotenoids, and other phytohormones, such as gibberellin, strigolactone, and abscisic acid. It is indeed a case that the MVA pathway-derived isoprene is responsible for the synthesis of the phytosterol precursor, squalene (a triterpene), via geranyl pyrophosphate (GPP) and farnesyl pyrophosphate (FPP), which are the precursors of monoterpenes and triterpenes, respectively [22,23]. FPP synthase (FPPS) and squalene synthase (SQS) catalyze these sequence reactions, which follow the epoxidation of squalene into 2, 3-oxidosqualene by squalene epoxidase (Figure 1Bi).
2.2. Condensation of Isoprene into Triterpenoids and Their Epoxidation

Isoprene, with a five-carbon atom, condenses together to generate monoterpenes (C10), sesquiterpenes (C15), diterpenes (C20), and triterpenes (C30). Triterpenes serve as precursors for phytosterol synthesis. Isoprene from the MEP pathway catalyzes the synthesis of monoterpenes, diterpenes, chlorophyll, carotenoids, and other phytohormones, such as gibberellin, strigolactone, and abscisic acid. It is indeed a case that the MVA pathway-derived isoprene is responsible for the synthesis of the phytosterol precursor, squalene (a triterpene), via geranyl pyrophosphate (GPP) and farnesyl pyrophosphate (FPP), which are the precursors of monoterpenes and triterpenes, respectively [22,23]. FPP synthase (FPPS) and squalene synthase (SQS) catalyze these sequence reactions, which follow the epoxidation of squalene into 2,3-oxidosqualene by squalene epoxidase (Figure 1Bi).

2.3. Phytosterol Synthesis

The biosynthesis of phytosterol exhibits a parallel pathway of cholesterol synthesis in eukaryotic cells [24]; 2,3-oxidosqualene serves as a common precursor for all sterol synthesis i.e., sterols like cholesterol in humans, ergosterol in fungi and phytosterols in plants. The biosynthesis of cholesterol and ergosterol is catalyzed by lanosterol synthase (LAS), whereas phytosterol synthesis from oxidosqualene is catalyzed by cycloartenol synthase (CAS) [25]. As in plant species, seaweeds metabolize 2,3-oxidosqualene to phytosterol by CAS and exhibit the hybrid cholesterol pathway as well, indicating an evolutionary relationship between these two phototrophic organisms [14].

Numerous studies have highlighted the importance of the CAS gene in phytosterol biosynthesis. In extensive research by feeding experiments using $[6-^{13}C_2]3^{13}CH_3$ MVL, Ohyama et al. [26] demonstrated that a mere 1.5% of sitosterol, encoded by the LAS1 gene, emphasizes its crucial role in the biosynthesis of phytosterols. Cycloartenol is metabolized into 24-methyleneophenol through six enzymatic reactions, such as methylation, double demethylation, double isomerization, and a reduction. From 24-methyleneophenol, the pathway branches off into two separate pathways, giving rise to episterol and A7 avenasterol via 24-ethylidenelophenol and end up in campesterol and β-sitosterol, respectively.
Stigmasterol is synthesized directly from -sitosterol, whereas campesterol is converted into brassinolide through subsequent reactions [24] (Figure 1Bii).

3. Extraction and Characterization of Phytosterols

Extraction techniques are proficient in separating the soluble metabolites of seaweed using suitable solvents [27]. The isolation techniques to be used for the extraction of phytosterols generally depend on the type of phytosterols (free, glycosylated, and esterified) and the nature of the matrix [28]. In each technique, optimized experimental conditions and adequate parameters are required to attain the appropriate quantity and higher yields from seaweed extract. The quality of an extract is substantially influenced by various factors, such as plant/seaweed material, solvent, extraction procedure, and others [29]. There are two common extraction techniques, namely conventional and non-conventional extraction (Figure 2) [30]. Conventional techniques usually employ a large volume of organic solvents to extract adequate analytes from samples that are required for further analysis. Nonetheless, the utilization of a higher volume of organic solvents may have a negative impact on human health and the environment. Furthermore, conventional techniques are reported to possess several limitations, such as the necessity of solvents with very high purity, an extended period of time for extraction, low selectivity of extraction, requirement of solvent evaporation and thermal decomposition of heat liable compounds. These limitations demanded the discovery of new extraction techniques with relatively very low utilization of organic solvents and more advantages than conventional techniques [31].

![Figure 2. An overview of phytosterol extraction and characterization methods.](image)

Soxhlet extraction is one of the conventional techniques, and remains the most preferred extraction technique for phytosterols, still, today [32,33]; it serves as a standard to many newly developed extraction techniques (Table 1) [31]. For example, Poulose et al. [32] extracted phytosterols from the red seaweed *Gelidium spinosum* using the Soxhlet method and revealed the presence of stigmasterol, with a mass of 412.69 g/mol, through Fourier transform infrared (FTIR) and gas chromatography–mass spectrometry (GC–MS). In addition, maceration is another common conventional technique, which is stated to be simple and cost-effective for phytosterol extraction [34].
Table 1. Examples of phytosterols identified from seaweeds.

| Source | Extraction Method | Methods of Analysis | Identified Phytosterols | References |
|--------|-------------------|---------------------|-------------------------|------------|
| Gelidium spinosum | Soxhlet method | FTIR and GC–MS | Stigmasterol | [32] |
| Saccharina latissima | saponified extract | GC–MS | cholesterol, desmosterol, 24-methylenecholesterol, fucosterol, cycloartenol, and unknown Δ5-sterol | [35] |
| Pelorina decipiens, Plocamium cartilagineum, Iridaea cordata, and Pyropia endiviifolia | alkaline hydrolysis | GC–MS | cholesterol, brassicasterol, campesterol, stigmasterol, β-sitosterol, and fucosterol | [33] |
| Ecklonia radiata | alkaline saponification | LC-MS/MS and GC–MS | fucosterol, Sitostanol, 24α-methyl cholesterol, and 24α-ethyl cholesterol | [36] |
| Padina australis and Stoehospermum marginatum, and Alnifitiopsis pygmaea | acid and alkaline hydrolysis followed by solvent extraction, derivatization, and GC determination | gas chromatography coupled with a flame ionization detection system (GC–FID) | sitostanol, campestanol ergosterol, campesterol, delta-5-avenasterol, stigmasterol, sitosterol, cholesterol, and 24-methylenecholesterol | [37] |
| Adenocystis utricularis, Desmarestia confervoides, Curdina racovitzae, Myriogramme mangunii, and Ulva intestinalis | Soxhlet method | GC–MS and FT-IR | fucosterol, cholesterol, and hydroxymethylcholesterol | [38] |
| Phaeophyta (Cystoseira barbata, Cystoseira compressa, Fucus viridosides) and chlorophyta (Codium bursa) | agitation-assisted extraction and pressurized liquid extraction | TLC | cholesterol, brassicasterol, campesterol, campestanol, β-sitosterol, fucosterol, and isofucosterol | [39] |
| Cystoseira trinodis | solvent extraction and column chromatography | $^1$H, $^{13}$C NMR, heteronuclear multiple-bond correlation (HMBC), heteronuclear single-quantum coherence (HSQC), GC–MS, and electron ionization-mass spectra (EI-MS) | saringosterol, β-sitosterol | [40] |
| Sargassum horneri | high-speed countercurrent chromatography | NMR | fucosterol and saringosterol | [41] |
| S. fusiforme | Folch method | GC–MS | 24(S)-Saringosterol | [42] |
| Halimeda tuna, Codium bursa, and Cystoseira barbata | solvent extraction | GC and GC–MS | fucosterol, campesterol and β-sitosterol | [43] |
| Source                                      | Extraction Method                          | Methods of Analysis                   | Identified Phytosterols                      | References |
|--------------------------------------------|-------------------------------------------|---------------------------------------|---------------------------------------------|------------|
| Sargassum elegans                          | solvent extraction and column chromatography | NMR ($^1$H and $^{13}$C), IR and mass spectral data | β-sitosterol, fucosterol                     | [44]       |
| Phaeophyta (Cystophora pectinata, Pyelospora comaosa, Scytothalia dorycarpa, Carpoglossum confluens, E. radata, Sargassum lacerfolium, Perithalia caudata, Codium harveyi, Scytothalia dorycarpa, Hypnea valida, Cystophora monilfera, Hormosira banksia, Myrioedema integrifolium, Epiphytic algae sp., Cystophora subfarcinata), Rhodophyta (Austrophyllis harveyana, Rhodophyllis membranaecea), and chlorophylla (Codium fragile) | maceration post-chromatographic derivatization and HPTLC | β-sitosterol | [45]       |
| Ascoseira mirabilis, A. utricularis, Desmarestia anceps, and Phaeurus antarcticus | saponification | GC-MS | cholesterol, desmosterol, brassicasterol, campesterol, stigmasterol, fucosterol, and β-sitosterol | [46]       |
| Ecklonia stolonifera                       | silica gel column chromatography           | $^1$H and $^{13}$C NMR                | fucosterol                                  | [47]       |
| Rhodophyta (Gracilaria verniculophylla, Pterocladiella tenuis, Palisada intermedia, Chrysymenia wrightii, Gracilaria elegans, Grateloupia asiatica, Laurencia okamurae) and Phaeophyta (Eckloniopsi radicosa, Sargassum thunbergia, Ecklonia kurome, Eisenia arborea, Sargassum piluliferum, S. fusiforme, U. pinnatifida, Ecklonia cava) | saponification HPLC with fluorescence detection | cholesterol, β-sitosterol, ergosterol, stigmasterol, and fucosterol | [48]       |
| S. horneri                                 | total lipid extraction using methanol      | RP-HPLC                               | fucosterol                                  | [49]       |
| Hizikia fusiforme                          | ethanol extraction and chromatographic separation | LC/ electrospray ionization (ESI)-MS | fucosterol                                  | [50]       |
Table 1. Cont.

| Source | Extraction Method | Methods of Analysis | Identified Phytochemicals | References |
|--------|-------------------|---------------------|--------------------------|------------|
| A. utricularis, Ascoseira mirabilis, Cystosphaera jacquinoti, D. anceps, Durvillaea antarctica, and Himantothallus grandifolius | ultrasound irradiation | LC-MS/MS | ergosterol, brassicasterol, fucosterol, β-sitosterol, campesterol, cholesterol, and stigmasterol | [6] |
| Porphyra dentata | methanol extraction and silica gel column chromatography | HPLC- evaporative light scattering detector (ELSD) | cholesterol, β-sitosterol, and campesterol | [51] |

Apart from these conventional techniques, phytosterol extraction has also been shown to be accomplished using many other non-conventional extraction techniques, such as microwave-assisted extraction (MAE), ultrasonic-assisted extraction (UAE), enzyme-assisted extraction (EAE), pulsed electric field-assisted extraction (PEFAE), pressurized liquid extraction (PLE), and supercritical fluid extraction (SFE) (Figure 2) [31]. For instance, Xiao et al. [52] have employed MAE with high-speed countercurrent chromatography (liquid-liquid partition chromatography) and a UV detector to extract, separate, and purify phytosterols from the edible brown seaweeds S. fusiforme and U. pinnatifida. By employing these extraction and chromatographic techniques, the authors were able to obtain 1.5 mg of 24-methylenecholesterol and 13 mg of fucosterol from 15 g of U. pinnatifida and 0.3 mg of 24-methylenecholesterol and 4.6 mg of fucosterol from 15 g of S. fusiforme. Remarkably, Roiaini et al. [53] have performed a comparative analysis of various phytosterol extraction techniques on cocoa butter such as Soxhlet, ultrasonic, supercritical carbon dioxide, and supercritical carbon dioxide with co-solvents. The authors concluded that the highest phytosterol content was obtained when using supercritical carbon dioxide with a cosolvent.

The separation process usually follows the extraction process. In this context, thin-layer chromatography (TLC) and high-performance liquid chromatography (HPLC) techniques are extensively used separation techniques (Figure 2). After the separation process, phytosterols in the analytes are confirmed via various analytical methods. Preliminary screening of phytosterols can be performed through Salkowski test [54], in which the formation of brown ring confirms the presence of phytosterols. Besides the conventional Salkowski method, FTIR and nuclear magnetic resonance are widely utilized to analyze phytosterols. However, precise determination of phytosterols could be achieved through employing mass spectrometry analysis [32,33]. For example, GC–MS analysis of the ethanolic extracts of 18 seaweeds revealed the presence of 14 compounds including 3 sterols, cholestanol, β-sitosterol, and fucosterol [55]. In another study, the presence of a significant amount of fucosterol in brown seaweed C. barbata and the highest level of β-sitosterol in H. tuna and C. bursa were revealed through GC–MS analysis [43]. Similarly, Santi et al. [33] have isolated phytosterols from four red seaweeds namely P. decipiens, P. endiviifolia, I. cordata, and P. cartilagineum using alkaline hydrolysis extraction method and showed the presence of sterols such as fucosterol, β-sitosterol, stigmasterol, brassicasterol, cholesterol and campesterol through GC–MS analysis. Correspondingly, Kendel et al. [56] have also employed GC–MS analysis to reveal the presence of phytosterols such as fucosterol, isofucosterol, brassicasterol, chondrillasterol and cholest-4-en-3-one in the chloroform/methanol extracts of U. armoricana and S. chordalis.

In another study, Bouzidi et al. [57] used 1H nuclear magnetic resonance (NMR) to analyze fractions of the marine brown seaweed C. foeniculacea that were extracted using a chloroform methanol water mixture and isolated using reversed-phase HPLC (RP-HPLC). Through 1H NMR analysis, the authors revealed the presence of fucosterol and an epimeric combination of saringosterol in the seaweed fractions. Recently, a one-step preparative method for separation of phytosterols was put forward by Xia et al. [41] wherein the authors
successfully utilized the high-speed countercurrent chromatographic method to extract fucosterol (23.7 mg), and saringosterol (3.1 mg) from the crude extract of *S. horneri* using two-phase solvent system. Furthermore, the authors have characterized the phytosterols through $^1$H and $^{13}$C NMR structural analysis. In addition, high-performance thin-layer chromatography (HPTLC, a technique for target-directed identification of active leads in a group of compounds) combined with biochemical and microchemical derivatizations revealed the presence of phytosterols and phenolic lipids in the ethyl acetate extract of 19 marine algae samples in addition to displaying bioactivity such as antioxidant, α-amylase and acetylcholinesterase inhibitory activities [41]. In a study by Oh et al. [47], methanolic extract of *E. stolonifera* was fractionated using various solvents and the fraction with strong bioactivity was further purified to yield fucosterol (99% purity, determined by HPLC) and identified by $^1$H and $^{13}$C NMR methods to study the neuroprotective effects of fucosterols.

Through various techniques, the sterol profiling of diverse seaweeds from different regions has already been done by many research groups, which has subsequently helped to gratify the demand for phytosterols in the global market. By uncovering the concentration of diverse sterols in different seaweeds of different regions during various seasons, the optimal techniques and suitable seaweeds could be easily identified for the preparation of particular phytosterols in large quantities. Furthermore, the extraction, isolation and analytical techniques are continually evolving, which simplifies the overall preparation process of phytosterols eventually and also proves to be more competent, fast and eco-friendly than conventional techniques.

### 4. Health Benefits and Biomedical Applications of Phytosterols

Phytosterols are renowned for their cholesterol-lowering activity, which potentially reduces the intestinal absorption of cholesterol by up to 30–50%. One of the major mechanisms driving the hypocholesterolemic activity of phycosterols is reported to be related to the competition of phytosterols with structurally similar mammalian cholesterol in the intestinal lumen, which, in turn, reduces the quantity of cholesterol accessible for intestinal absorption. Several other mechanisms underlying the hypocholesterolemic activity of phytosterols have also been previously reported, which include (i) alterations in the expression level of genes encoding sterol-carrying proteins, such as the ATP-binding cassette transporters ABCG5 and 8, that increase the discharge of cholesterol from enterocytes into the intestinal lumen or Niemann–Pick C1-like 1 protein that decrease the transfer of cholesterol to enterocyte; (ii) a reduction in the esterification of cholesterol in enterocyte; and (iii) an increase in the level of cholesterol elimination from the body via transintestinal cholesterol excretion [58]. For instance, the intragastric administration of sitosterol/ fucosterol (25 mg) and cholesterol (25 mg) encompassing an emulsified lipid meal was identified to interfere with the absorption and micellar solubility of cholesterol in rats [59]. Additionally, phytosterols are also reported to act as anticonvulsants, antidepressants, hepatoprotectants, angiotensin-converting enzyme inhibitors, and regulators of cholesterol homeostasis [14]. For example, the *S. fusiforme*-derived fucosterol was found to exhibit antidepressant activities in mice by curbing the immobility time for 30 min in tail suspension test and forced swimming test. The pathogenesis of depression is mainly hypothesized to be related to the reduction in the levels of monoamine neurotransmitters such as dopamine, serotonin and noradrenaline. Interestingly, fucosterol was found to elevate the levels of these monoamine neurotransmitters, which affirmed its antidepressant activity [60]. In another investigation, oral administration of 30 mg/kg of fucosterol from *Pelvetia siliquosa* was found to exhibit inhibitory activity against streptozotocin-triggered diabetes in rats by significantly reducing serum glucose level and the accumulation of sorbitol in lenses. Further, oral administration of 300 mg/kg of fucosterol was identified as reducing blood glucose concentration and glycogen degradation in epinephrine-induced diabetic rats [61]. Altogether, the myriad health-promoting effects of phytosterols open the door for the development of new drugs for treating several chronic diseases and the fabrication of phytosterols-enriched functional foods that could be used as a part of a healthy routine. Nevertheless, the health benefits
of phytosterols are not only limited to cholesterol-lowering potential, but also extend to anti-cancer, antioxidant, anti-inflammatory, anti-adipogenic, anti-obesity, anti-diabetic, anti-Alzheimer, and anti-atherosclerosis activities. The different biological properties and biomedical applications of phytosterols are provided in Figure 3.

Figure 3. Biological properties and biomedical applications of phytosterols.

4.1. Phytosterols as Antioxidative Agents

Reactive oxygen species (ROS) and free radicals are perpetually generated and their implications in pathobiology are associated with various diseases, including cancer, neurodegenerative and cardiac diseases [62]. The human body is endogenously equipped with enzymatic antioxidants, such as superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase (GR), and catalase (CAT), to counteract the effects of oxidation. A transcriptional regulator, nuclear erythroid 2-related factor 2 (Nrf2), mediates the expression of antioxidant response elements during oxidative stress [63]. In addition, non-enzymatic antioxidants are shown to boost the antioxidant defense mechanisms and thereby aid in ROS elimination. The antioxidant supplements from seaweeds are reported to reduce the risk of cancer, cardiovascular, and other degenerative diseases in humans [63–65]. Particularly, fucosterols from brown seaweed are gaining interest due to their exceptional antioxidant properties. Studies have suggested several mechanisms for the antioxidant activity of fucosterol, including increased activities of free radical scavenging enzymes such as GPx, CAT and SOD [61], inhibition of ROS generation by suppressing iNOS (Inducible nitric oxide synthase) and COX-2 (cyclooxygenase-2) [66,67], and inhibitory activities against biomarkers (β-secretase, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE)) of Alzheimer’s disease [68]. The general antioxidant mechanism of action of phytosterol is illustrated in Figure 4.
Figure 4. Schematic diagram representing the antioxidant mechanism of fucosterol. Up-regulation of antioxidant enzymes such as HO-1 (heme oxygenase-1), SOD, and CAT, via the Nrf2/ARE signaling pathways. The left image indicates the normal physiological conditions in which Nrf2 bound to keap1 in the cytosol undergoes degradation by the ubiquitination process.

Phaeophyta, a brown seaweed, with higher amounts of fucosterol, exhibited considerable antioxidant activity in the 2, 2-diphenyl-1-picrylhydrazyl (DPPH) assay [48]. Fucosterol, one of the major components of the brown seaweed Padina gymnospora ethyl acetate extract, exhibited promising antioxidant activity in β-carotene bleaching (BCB) and total reducing activity (TRA) assays [69]. Fernando et al. [70] have reported that fucosterol (from brown seaweed S. binderi) treatment in HaCaT keratinocytes and HDF fibroblasts cells significantly decreased intracellular ROS levels and increased cell viability during exposure to particulate matter (PM). In another study by Fernando et al. [71], fucosterol increased the level of enzymatic antioxidants, such as SOD, CAT, and HO-1, as well as the transcriptional regulator Nrf2 in A549 cells in the nucleus. Similarly, Choi et al. [72] reported that fucosterol, obtained from E. stolonifera and Eisenia bicyclus, hugely inhibited the generation of intracellular ROS and ameliorated the levels of glutathione in tert-butyl hydroperoxide and tacrine-treated HepG2 cells. Jiang et al. [73] reported the dose-dependent intensification of intracellular ROS in a fucosterol-treated HeLa cervical cancer cell line. Fucosterol from S. horneri showed strong free radical scavenging activities in DPPH and 2,2 azino-bis3-ethylbenzthiazoline-6-sulfonic acid (ABTS) assays. In addition, fucosterol attenuated the oxidative actions in HT22 and BV2 cells by enhancing the HO-1 and Nrf2 levels in the cytoplasm and nucleus, respectively [74]. Similarly, fucosterol from P. borgana, a brown seaweed, significantly upregulated the antioxidant proteins such as Nrf2, and HO-1 and downregulated the Kelch-like ECH-associated protein-1 (Keap1) in the RAW 264.7 macrophage cell line induced with PM [67], in addition to anti-inflammatory activity. Remarkably, Ibrahim et al. [75] revealed the antioxidant property of sterol hydrocarbon, obtained from brown seaweed Taonia atomaria, through DPPH, ABTS, and total antioxidant capacity (TAC) assays. The study also unveiled the anti-inflammatory and anticancer (against human liver, breast, ovarian, and colon cancer cell lines) activities of T. atomaria.
sterol hydrocarbons. Nevertheless, it was suggested that the anti-inflammatory and anticancer activities may be due to strong antioxidant properties, indicating the effectiveness of sterols in oxidative stress-related diseases. These research findings demonstrate the overwhelming antioxidant property of phytosterols, especially fucosterol and, moreover, these antioxidants could function against oxidative stress-associated diseases. Vanbrabant et al. [76] found that 24(R, S)-saringosterol, an oxidative product of fucosterol, has higher antioxidant activity than fucosterol; however, more research is needed to confirm the antioxidant potential of 24(R, S)-saringosterol.

4.2. Phytosterols as Antimicrobial Agents

Phytosterols have antimicrobial activities against a wide range of human pathogens, including bacteria, fungi, viruses, and protozoa. The lipophilic extract of Bifurcaria bifurcata, with a considerable amount of fucosterol displayed antibacterial activities against both Gram-positive (Staphylococcus aureus and Staphylococcus epidermidis) and Gram-negative bacteria (Escherichia coli and Pseudomonas aeruginosa). Subsequently, the synergistic analysis of the extract with antibiotics significantly reduced the minimal inhibitory concentrations of the tested antibiotics [77]. Intriguingly, a cholesterol derivative, 24-propylidene cholest-5-en-3β-ol, obtained from the red algae Laurencia papillosa displayed antibacterial activity against S. aureus, Bacillus subtilis, E. coli, and P. aeruginosa. Furthermore, it exhibited strong antibacterial activity against the clinical isolates of Klebsiella pneumoniae, Shigella flexineri, E. coli, and P. aeruginosa [78]. In another study, assessment of the antimicrobial potential of seaweed extracts (A. urticulalis, C. racovitzae, and U. intestinalis) against S. aureus, E. coli, and Salmonella typhimurium revealed noteworthy effects. Moreover, the study also revealed the promising antioxidant property of the seaweed extracts obtained from D. confervoides [38]. Correspondingly, C. cylindracea (green seaweed) extract containing sterols in major proportions has been reported to showcase antibacterial and antioxidative properties [79]. Apart from that, the evaluation of critical sterols such as campstereol, β-sitosteryl, stigmasteryl, epicoprostanol, etc. against a wide range of bacteria revealed notable antibacterial properties [80]. The authors also reported a higher rate of growth inhibition in Gram-negative bacteria (Vibrio, Pseudomonas, and Bacillus spp.) than Gram-positive bacteria. Conversely, the crude methanolic extracts of eight brown seaweeds (Sargassum spp., and Hormophausa cuneiformis) had more promising antibacterial activity against Gram-positive bacteria (S. pneumoniae, B. cereus and S. aureus) than Gram-negative bacteria. Additionally, the crude extracts displayed antifungal activity against Trichosporon mucoides, Candida membranaefaciens, and Cryptococcus neoformans. An exploration of chemical constituents revealed fucosterol as the abundant compound, along with 24-ketocholesterol, saringosterol, revealed noteworthy effects. Moreover, the study also revealed the Salmonella typhimurium activity [86]. Similarly, assessment of antimalarial activity against the FCM29 strain of P.
*Plasmodium falciparum* using the crude extract of *S. incisifolium* significantly inhibited the growth of the organism, with an IC$_{50}$ value of 57.80 ± 1.91 µg/mL [81]. Overall, these findings underscore the antimicrobial properties of seaweed-based phytosterols. Generally, sterols target the cell walls of the microbes. It blocks the biosynthesis of the cell wall and makes the cells more susceptible to osmotic lysis [87,88]. However, the mechanism of action remains poorly studied in seaweeds-derived phytosterols.

### 4.3. Phytosterols as Anti-Inflammatory Agents

Chronic inflammation generally develops as part of the sequence of cellular events following acute inflammation in humans and animals. The important microcirculatory responses, including the recruitment of leukocytes, vascular permeability modulation, and releasing inflammatory mediators, are responsible for developing and maintaining inflammation [89,90]. The inflammatory cytokines, including tumor necrosis factor-α (TNF-α), cyclooxygenase (COX-2), interferon gamma (IFNγ), interleukin (IL)-1β, IL-6, IL-8, and IL-10, are the key modulators of low-grade chronic inflammation [91,92]. Lipopolysaccharide (LPS) triggers an immune response by interacting with the membrane receptor to enhance the production of cytokines. The excessive production of such inflammatory mediators contributes to chronic inflammatory disorders. Chronic inflammation has been subjected to the physiopathology of several diseases, including cancer, hepatitis, obesity, diabetes, metabolic syndrome, arthritis, degenerative neurological disorders, and cardiovascular diseases [93]. Several bioactive natural compounds have shown anti-inflammatory activity to protect against chronic diseases. Recently, numerous anti-inflammatory agents have been isolated from marine algae with protective efficacy against chronic inflammation [94,95]. In particular, the mechanisms involved in counteracting neuroinflammation include inhibiting the expression of pro-inflammatory enzymes [96], reducing inflammatory mediators, modulating MAPK pathways [97], and NF-κB activation [98]. Among the marine algae derivatives, phytosterols have been described as efficient anti-inflammatory agents. Among chronic inflammations, inflammatory bowel diseases (IBDs) cause serious problems in younger generations, as they cause serious illnesses and are proven to be fatal, if untreated [99]. In the hunt for natural compounds to treat such inflammations, phytosterols had been proven to augment the clinical remission of IBDs in mice [100]. However, there is no report that can link these effects to macroalgae-derived phytosterols.

Fucosterol and its derivatives are the most common phytosterols, majorly found in brown seaweed [7]. Several studies have investigated the anti-inflammatory potential of fucosterol and its derivatives. For instance, fucosterol, isolated from the brown seaweed *E. bicyclis*, has been shown to attenuate the expression of inflammatory mediators such as inducible nitric oxide (NO) synthase and COX-2 in LPS-stimulated macrophages [66]. Sun et al. [101] also reported that fucosterol shows anti-inflammatory activity by suppressing TNF-α, IL-6, and IL-1β expressions. Fucosterol also attenuates the LPS-induced inflammatory response by suppressing the production of TNF-α, IL-6, and IL-1β and nuclear factor-κB (NF-κB) activation in LPS-induced alveolar macrophages [102]. NF-κB has been considered a prototypical pro-inflammatory signaling pathway. The activation of the NF-κB, by nuclear translocation of cytoplasmic complexes, plays a key role in inflammation via the induced transcription of genes encoding pro-inflammatory mediators [103]. Also, the anti-inflammatory agent fucosterol has been isolated from the most abundant marine brown alga, *S. binderi*. Fernando et al. [71] have reported that the fucosterol from *S. binderi* inhibited chronic inflammatory responses by suppressing the production levels of TNF-α and IL-6, COX2, and prostaglandin E2, the nuclear translocation of both p65 and p50, and the activation of the p38 mitogen-activated protein kinase (MAPK) pathway [71]. Alzheimer’s disease, inflammatory bowel disease, and rheumatoid arthritis are postulated to be synchronized, in part, by MAPK p38 [104–106]. The activated p38 pathway triggers the production of pro-inflammatory mediators (IL-1β, TNF-α, IL-6, and COX-2) that direct the remodeling of connective tissue in pathological conditions by encoding adherent proteins along with other inflammatory-related molecules [107]. Another study found
that fucosterol, isolated from *U. pinnatifida*, reduced the formation of pro-inflammatory cytokines (iNOS, TNF-α, and IL-6) and, subsequently, inhibited LPS-stimulated NO production by suppressing the activation of NF-κB and the phosphorylation of p38 MAPK in macrophages [108]. Phytosterols present in seaweed have been shown to be neuromodulators in the central nervous system (CNS). By stimulating synapse remodeling, improving neuroinflammation, and suppressing neurotoxic protein accumulation in the CNS, seaweed-derived phytosterols can be considered an exciting therapy for the treatment of neurodegenerative diseases [13]. Alzheimer’s disease is attributed to the accumulation of the toxic protein amyloid-β (Aβ) in the CNS. Although Aβ is crucial for neuronal survival and synaptic plasticity, high concentrations eventually lead to cell death and neurotoxicity [109]. Wong and colleagues reported that fucosterol also protects against Aβ-associated neuroinflammation via attenuating the production of inflammatory mediators in Aβ-induced microglial cells [68]. Aβ peptide was found to trigger pro-inflammation through the activation of p38 MAPK [110]. Chronic microglial activation by Aβ stimulated the expression of inflammatory mediators such as TNF-α, IL-1β, IL-6, NO, and prostaglandin E2, which could lead to the neuroinflammation known as Alzheimer’s disease [111,112]. Also, the anti-inflammatory agent fucosterol has been shown to be a non-competitive inhibitor of the enzyme β-secretase, which is important for the production of toxic Aβ monomers [113].

Saringosterol, another important seaweed-derived phytosterol, has been found to diminish the formation of neuronal Aβ while triggering microglia-mediated Aβ clearance [114]. The brown seaweed *S. fusiforme* contains high ranges of 24(S)-saringosterol. Saringosterol reduced the load of Aβ plaque and improved cognitive performance in an AD animal model [113]. However, with the exception of saringosterol, seaweed-derived fucosterol, fucoxanthin, and fucoidan have been reported to act against memory deficits [115]. Overall, these findings highlight the anti-inflammatory properties of seaweed-derived phytosterols.

### 4.4. Phytosterols as Anticancer Agents

Foods enriched with phytosterols and their oxy-derivatives could help to prevent tumor growth in humans. Phytosterols play various roles in the human body to control the progression of the numerous cancer types [116]. In gastric cancer cells (SNU-1), stigmasterol induces mitochondrial-mediated apoptosis, through which it suppresses cancer development. The activation of the apoptotic pathway by stigmasterol was evidenced by increased Bax and decreased Bcl-2 expression. In a concentration-dependent manner, it also reduced cancer cell migration and caused G2/M cell cycle arrest. In addition, stigmasterol suppresses the JAK/STAT signaling pathway, which is thought to be responsible for its anticancer effect in SNU-1 cells [117]. In Swiss albino mice, the effect of stigmasterol on 7,12-dimethylbenz[a]anthracene (DMBA)-induced skin cancer was examined. In the stigmasterol-treated groups, the tumor size and the total number of papillomas were decreased. Meanwhile, GSH, SOD, and catalase activity were all elevated in the skin of stigmasterol-treated mice. Furthermore, stigmasterol treatment dramatically reduced high levels of lipid peroxide and DNA damage in the control group. This implied that stigmasterol protected against DMBA-induced genotoxicity by acting as an antigentoxic and antioxidant [118]. In a time- and dose-dependent way, stigmasterol dramatically reduced the viability of gastric cancer cell lines, such as SGC-7901 and MGC-803. Changes in the expression of the apoptotic key proteins Bax and Bcl-2, the cleavage of caspase-3, and poly (ADP-ribose) polymerase (PARP) have indicated apoptotic-mediated cell death upon treatment with stigmasterol in both cell lines [119]. LC3-II acts as a marker for an autophagic activity [120]. Treatment with stigmasterol resulted in an increase in LC3-II levels, indicating the activation of autophagy. Similarly, beclin 1 is an upstream molecule that is essential for autophagosome formation and that plays a key role in autophagy induction [121]. The expression of beclin-1 was also enhanced upon stigmasterol treatment, which further confirmed autophagy activation (Figure 5). As a result, stigmasterol’s anti-
cancer impact in gastric cancer cells is dependent on apoptotic and autophagy-mediated mechanisms [119]. The overall mechanisms of the anticancer activities of phytosterols have been illustrated in Figure 5.

Figure 5. Anticancer mechanisms of phytosterols. The different modes of action giving rise to the anticancer properties of phytosterols act in different gene pathway. Controlled regulation of genes involved in antioxidation, apoptosis and antimitosis restricts the growth of the cancer cells.

Campesterol inhibited the aggregation of the human ovarian cancer cell lines ES2 and OV90. In both cell lines, it increased the expression of proapoptotic proteins, promoted caspase 3 and caspase 9 cleavage, and increased the expression of cytochrome C, BAK, and BAX. Campesterol also elevates the levels of autophagy-related proteins like BECN1, phosphorylated (p)-ULK1, ATG5, and LC3B (Figure 5). The amount of calcium in ES2 cells was observed to be higher after treatment with campesterol. In addition, campesterol exposure elevates the expression of the ER–mitochondria axis proteins, such as VAPB, FAM82A2, GRP75, VDAC, IP3R1, and IP3R2 [122]. The new formation of capillary blood vessels is called angiogenesis. It is considered as major hallmark of cancer development and metastasis. The major steps in angiogenesis include the proliferation of endothelial cells, differentiation, migration, the destruction of the extracellular matrix, tube-like structure
formation, and the formation of vessel branches [123]. Campesterol has been shown to reduce bFGF-induced pathological angiogenesis in HUVEC endothelial cells. The CAM assay confirmed that campesterol significantly hindered the creation of new embryonic blood vessels without impacting the established vasculature [124].

Brassicasterol treatment has been found to reduce the viability of LNCaP and PC-3 cells. It reduced the number of LNCaP cells and suppressed the expression of prostate-specific antigen and androgen receptors. Also, brassicasterol caused sub-G1 phase arrest. The expression of PARP was inhibited by brassicasterol treatment, during which induced cleaved caspase-3 expression was noted. Brassicasterol inhibits cell migration in LNCaP cells, as well [125]. Furthermore, it inhibited n-butyl-(4-hydroxybutyl) nitrosamine (BHBN) and SS-induced carcinogenesis. Cyclin D1 has been found to be overexpressed in bladder epithelial cells and it is a key player in the cell cycle [126]. When compared to the carcinogenesis group, the expression levels of cyclin D1, c-fos, and c-jun were significantly lower in brassicasterol-treated mice. This indicates the occurrence of cell cycle arrest. Prostaglandin E2 (PGE2), which is produced by the enzyme cyclooxygenase-2 (COX-2), also plays a role in the development of bladder cancer [127]. Brassicasterol treatment significantly reduced the expression of COX-2 in rats with comparison to the cancer-induced rats. Testosterone has a key role in bladder cancer development, while 5-α-reductase converts testosterone to the active metabolite dihydrotestosterone (DHT). DHT has androgenic properties because it interacts with the nuclear androgen receptor (AR). When rats treated with brassicasterol were compared to cancer-induced rats, the expression level of 5-α-R1 was considerably lower. Similarly, treatment with brassicasterol also dramatically reduced the expression levels of 5-α-reductase type 2 (5-α-R2) and AR, compared with the cancer-induced rats. According to these findings, brassicasterol inhibits bladder carcinogenesis by acting on cell cycle-associated signaling and androgen signaling via several mechanisms [128].

β-Sitosterol treatment caused DNA fragmentation and tailing in the COLO 320 DM human colon cancer cell line. In COLO 320 DM cells, it also resulted in the production of free radicals. In vitro, β-sitosterol treatment dramatically reduced β-catenin and PCNA expression in COLO 320 DM cells. Similarly, in vivo, β-sitosterol treatment for 16 weeks significantly reduced the number of aberrant crypts and crypt multiplicity in DMH-treated rats [129]. At 48 h, β-sitosterol significantly inhibited cancer cell proliferation in MDA-MB-231 cells. It triggered G0/G1 arrest, as shown by lower levels of CDK4 and cyclin D1 proteins and higher levels of p21/Cip1 and p27/Kip1 proteins. Apoptotic activation was also confirmed by Bcl-2 downregulation and Bax upregulation. The depolarization of mitochondrial membrane potentials is caused by β-sitosterol-induced apoptosis [130]. The cytotoxic effects of seaweed-derived compounds pertaining to anticancer activity are listed in Table 2.

The effects of β-sitosterol on A549 cells was significant, with concentration- and time-dependent action. β-sitosterol-treated Swiss albino mice were healthy and showed no significant changes in behavior or mortality rate. A549 cells treated with β-sitosterol showed nuclear and DNA fragmentation with apoptotic morphological changes. β-sitosterol treatment caused the decreased expression of Bcl-2 and upregulated the expression of Bax protein; it also resulted in the cleavage of caspase-3 and PARP protein. β-sitosterol induced mitochondrial membrane depolarization and released cytochrome c, which confirmed that the mode of apoptosis induced by β-sitosterol in A549 cells was intrinsic. Furthermore, when cells were treated with β-sitosterol, the number of cells in the G2/M phase was increased [131]. The effect of β-sitosterol in A549 cells was mediated by elevated ROS, which was confirmed by the pretreatment of NAC. In cancer cells elevated levels of thioredoxin (Trx1) and thioredoxin reductase (TrxR1) play a role in ROS homeostasis [132]. β-sitosterol decreased the expression of both TrxR1 and Trx1 in A549 cells thereby causing oxidative stress and intrinsic mode of cancer cell death [133].
### Table 2. Cytotoxicity of seaweed-derived compounds toward anticancer activity.

| Seaweed Names | Cell Lines Used | Therapeutic Compounds | Anticancer Activity | References |
|---------------|-----------------|------------------------|---------------------|------------|
| *Ulva fasciata*, *Ulva lactuca*, *Amphiroa aniceps*, *Coralina mediterranea*, and *Sargassum filipendula* | human breast adenocarcinoma cell line (MCF-7) and colorectal carcinoma cell line (HCT-116) | palmitic acid, oleic acid, retinoic acid, dihydroactinidiolide, thiosemicarbazide, diisobutyl phthalate, and phytol | anticancer agents against human breast and colon cancers | [134] |
| *Sargassum spp.* | SMMC-7721, Huh7, and HCCLM3 liver | fucoidan | deactivates the integrin αVβ3/SRC/E2F1 signaling pathway; Antimetastatic | [135] |
| *Ulva lactuca*, *Codium tomentosum*, *Cystoseira crinita*, *Cystoseira stricta*, *Sargassum vulgare*, *Gelidium latifolium*, *Hypnea musciformis* and *Jania rubens* | human colorectal carcinoma (Caco2) and human corneal epithelial cells (HCEC) | polyphenols and flavonoids | human colorectal carcinoma | [136] |
| *Ecklonia maxima* | HeLa, H157 and MCF7 cancer cell lines | phlorotannins and sterol | cytotoxic activity | [137] |
| *Sargassum spp.*, *Turbinaria spp.* and *Padina spp.* | breast cancer (MCF-7) and colon cancer cells (WiDr) | fucoidan | showed potential selective cytotoxicity | [138] |
| *Sargassum hemiphyllum* | HCT116 | oligo-fucoidan | DNA damage; cell cycle checkpoint; prevents HCT116 tumorigenicity and regulate the cancer cell death | [139] |
| *Ulva lactuca* and *Eucheuma cottonii* | breast MCF-7 and colorectal HCT-116 cancer cells | steroids, glycosides, flavonoids, and tannins | anti-breast and anticolorectal cancer agents | [140] |
| *Carpodesmia tamariscifolia* | hepatocellular carcinoma Hep G2, AGS and HCT-15 cell lines | isololiolide | caspase-3 activation, decreased Bcl-2 levels, increased p53 expression and PARP cleavage | [141] |
| *Fucus vesiculosus* | human hepatoma cell line MHCC-97H | fucoidan | macrophages M2 anti-inflammatory reduction; inhibition of tumor cell migration | [142] |
| *Brown algae spp.* | MCF-7 cell line | phloroglucinol | decreased CD44+ cancer cell population, expression of CSC regulators such as Sox2, CD44, Oct4, Notch2, and β-catenin; inhibited KRAS and its downstream PI3K/AKT and RAF-1/ERK signaling pathway | [143] |
Table 2. Cont.

| Seaweed Names       | Cell Lines Used                      | Therapeutic Compounds | Anticancer Activity                                                                 | References |
|---------------------|--------------------------------------|-----------------------|-------------------------------------------------------------------------------------|------------|
| *U. pinnatifida*    | human hepatocellular carcinoma SMMC-7721 cells | fucoidan              | apoptosis via the ROS mediated mitochondrial pathway                                 | [144]      |
| *U. pinnatifida*    | PC-3 human prostate cancer cells      | fucoidan              | induced intrinsic and extrinsic apoptosis pathways                                    | [145]      |
| *Laminaria digitata*| HT-29 colon cancer cells              | laminarin             | induction of apoptosis; affected insulin-like growth factor (IGF-IR); decreased MAPK and ERK phosphorylation; decreased IGF-IR-dependent proliferation | [146,147] |
| *Sargassum muticum* | MCF-7 cells                          | *Sargassum muticum* methanol extract (SMME) | induced apoptosis; showed antiangiogenic activity in the chorioallantoic membrane (CAM) assay; antioxidant effects | [148]      |
| *Porphyra dentata*  | 4T1 cancer cells                     | cholesterol, β-sitosterol, and campesterol | induced apoptosis; decreased the ROS and arginase activity of MDSCs in tumor-bearing mice | [51]       |
| *Sargassum spp.*    | MCF-7 (breast cancer) and Hep-2 (liver cancer) cell line | ethanol extract       | induced cell shrinkage, cell membrane blebbing and formation of apoptotic bodies     | [149]      |
| *U. pinnatifida*    | A549 human lung carcinoma cells      | fucoidan              | induced apoptosis through down-regulation of p38, PI3K/Akt, and the activation of the ERK1/2 MAPK pathway | [150]      |
| *Sargassum oligocystum* | K562 and Daudi human cancer cell lines | fucoidans             | antitumor activity                                                                   | [151]      |
| *U. pinnatifidasporophylls* | leukemia A20 cells               | fucoidan              | T-cell mediated and NK cell response; tumor destruction by immune cells               | [152]      |
| *Amphiroa zonata*   | human leukemic cells                 | palmitic acid         | showed selective cytotoxicity                                                          | [153]      |

5. Safety of Phytosterols

Still today, clinical safety trials using both animal and plant models have not reported any negative effects of phytosterols [4]. Even though previous studies have specifically focused on the negative influence of phytosterol on sex hormones and organs, recent safety evaluations showed that phytosterol did not have an estrogenic impact on a rabbit animal.
model [154]. Subsequent studies also revealed that the daily administration of phytosterol (8.6 g) for 3 weeks to humans seems have no negative effect on gut microbiota and sex hormones [155]. Furthermore, it also demonstrated that the consumption of phytosterol at a very low dose does not have a serious effect on reproductive organs. However, some studies have demonstrated adverse clinical events related to plant sterols’ consumption [156]. It has been reported that consumption of phytosterol-enriched foods (olive oil and canola and soybean oils) decreases the life span of stroke-prone spontaneously hypertensive rats [157] but there is no report on seaweed-derived phytosterols. Other potential risks related with the intake of phytosterol is occurrence of rare inherited disorder phytosterolemia [158]. However, a myriad of research studies on phytosterol have inevitably proved that intake of phytosterol has potential health benefits, hence it is suggested that phytosterols-rich foods such as seaweed can be used as functional foods [159]. Phytoesters are sensitive to oxidation-like cholesterol, resulting in the formation of phytosterol oxidation products by enzymatic or non-enzymatic mechanisms during heat processing, storage, and human metabolism [160,161]. Despite the low concentration of cholesterol oxidation products in food, they have been demonstrated to cause cytotoxicity and genotoxicity. Therefore, the safety of phytosterol oxidation products has been studied and found to have cytotoxic effects on different cell lines [162].

6. Conclusions and Future Perspectives

Drug resistance, a natural phenomenon through which pathogenic microbes develop resistance against therapeutic agents, has become a major threat to public health. The development of resistance to conventionally available drugs has led to a search for novel therapeutic alternatives. At present, several synthetic drugs are being used, however, they often cause toxic side effects and become ineffective when used for a long time. Therefore, the search for new therapeutic agents from natural sources is expected to yield suitable alternatives. This review illustrated the implication of seaweed-derived phytosterols with their biosynthetic pathways and mechanisms of action in an effort to help in understanding their significant biomedical applications and valuable health benefits. Additionally, future drug designs, through the utilization of the structure determination and pharmacokinetics of seaweed sterols, will pave the way for developing novel therapeutic applications. The presence of significant amounts of steroids in seaweeds, especially cholesterol, campesterol, fucosterol, β-sitosterol, and stigmasterol, could contribute to several beneficial biological activities. Bioactive sterols as drugs could mediate multi-attribute target-oriented pharmacological activity, such as anticancer, antimicrobial, anti-inflammatory, and antioxidant activities. Consequently, phytosterols from seaweed were explored in order to establish the effectiveness of steroidal drug molecules in preventing drug resistance and reducing the side effects of pharmacological therapies. It is suggested that future research should focus on improving the bioavailability of phytosterols using various physical and chemical modifications. The preparation of phytosterol derivatives by chemical synthesis, such as enzyme-catalyzed synthesis and ionic liquid-catalyzed synthesis, is expected to increase their fat solubility. Physical changes, including the encapsulation of phytosterols in nano-delivery systems, can boost oral bioavailability by increasing solubility in the gastrointestinal tract, increasing absorption in targeted tissues, and ensuring sustained release. These can help us to improve the widespread use of these important natural bioactive compounds from seaweed in biomedical applications.

Author Contributions: Conceptualization: S.-I.S., P.R. and S.P.; Writing—original draft preparation: P.R., S.B., D.J.B., T.K.S., R.D., S.A. and S.P.; Writing—review and editing: P.R., S.B., T.K.S., R.D., S.A. and P.S.; Supervision: S.-I.S. and S.P.; Project Administration and Funding Acquisition: S.-I.S. All authors have read and agreed to the published version of the manuscript.

Funding: This study was carried out with the support of New Breeding Technologies Development Program (Project No. PJ014929022021), Rural Development Administration and 2021 Post-doctoral Fellowship Program (Project No. PJ014943012021), National Institute of Agricultural Sciences, Rural Development Administration, Korea.
Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Shirosaki, M.; Koyama, T. *Laminaria japonica* as a food for the prevention of obesity and diabetes. *Adv. Food Nutr. Res.* 2011, 64, 199–212. [PubMed]

2. Chen, Z.; Liu, J.; Fu, Z.; Ye, C.; Zhang, R.; Song, Y.; Zhang, Y.; Li, H.; Ying, H.; Liu, H. 24 (S)-Saringosterol from edible marine seaweed *Sargassum fusiforme* is a novel selective LXRI agonist. *J. Agric. Food Chem.* 2014, 62, 6130–6137. [CrossRef]

3. Kılıç, B.; Cirk, S.; Turan, G.; Tekoglu, H.; Koru, E. Seaweeds for Food and Industrial Applications. In *Food Industry*; IntechOpen: London, UK, 2013.

4. Ling, W.H.; Jones, P.J.H. Dietary phytosterols: A review of metabolism, benefits and side effects. *Life Sci.* 1995, 57, 195–206.

5. Lopes, G.; Sousa, C.; Valentão, P.; Andrade, P.B. Sterols in Algae and Health. In *Bioactive Compounds from Marine Foods: Plant and Animal Sources*; Wiley Online Library: Hoboken, NJ, USA, 2013; pp. 173–191.

6. Pereira, C.M.; Nunes, C.F.; Zambotti-Villela, L.; Streit, N.M.; Dias, D.; Pinto, E.; Colepicolo, P. Extraction of sterols in brown macroalgae from Antarctica and their identification by liquid chromatography coupled with tandem mass spectrometry. *J. Appl. Phycol.* 2017, 29, 751–757. [CrossRef]

7. Whittaker, M.H.; Frankos, V.H.; Wolterbeek, A.M.P.; Waalkens-Berendsen, D.H. Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: Clinical and experimental evidence. *Am. J. Med.* 2000, 109, 600–601. [CrossRef]

8. Sánchez-Machado, D.I.; López-Hernández, J.; Paseiro-Losada, P.; López-Cervantes, J. An HPLC method for the quantification of sterols in edible seaweeds. *Biomed. Chromatogr.* 2004, 18, 183–190. [CrossRef]

9. Dutta, P.C. *Phytosterols as Functional Food Components and Nutraceuticals*; CRC Press: Boca Raton, FL, USA, 2003.

10. Nes, W.D. Biosynthesis of cholesterol and other sterols. *Chem. Rev.* 2011, 111, 6423–6451. [CrossRef]

11. Wei, J.H.; Yin, X.; Welander, P.V. Sterol Synthesis in Diverse Bacteria. *Front. Microbiol.* 2016, 7, 990. [CrossRef]

12. Hannan, M.A.; Sohag, A.A.M.; Dash, R.; Haque, M.N.; Mohibullah, M.; Oktaviani, D.F.; Moon, I.S. Phytosterols of marine algae: Insights into the potential health benefits and molecular pharmacology. *Phytomedicine* 2020, 69, 153201. [CrossRef]

13. Schepers, M.; Martens, N.; Tiane, A.; Vanbrabant, K.; Streit, N.M.; Dias, D.; Pinto, E.; Colepicolo, P. Extraction of sterols in brown macroalgae from *Picea glauca* and their identification by liquid chromatography coupled with tandem mass spectrometry. *J. Appl. Phycol.* 2017, 29, 751–757. [CrossRef]

14. Chatzivasileiou, A.O.; Ward, V.; Edgar, S.M.; Stephanopoulos, G. Two-step pathway for isoprenoid synthesis. *Adv. Plant Biol.* 2013, 64, 665–700. [CrossRef]

15. Lohr, M.; Schwender, J.; Polle, J.E. Isoprenoid biosynthesis in eukaryotic phototrophs: A spotlight on algae. *Plant Sci.* 2012, 185, 9–22. [CrossRef] [PubMed]

16. Chatzivasileiou, A.O.; Ward, V.; Edgar, S.M.; Stephanopoulos, G. Two-step pathway for isoprenoid synthesis. *Proc. Natl. Acad. Sci. USA* 2011, 116, 506–511. [CrossRef] [PubMed]

17. Harder, J. Isoprene, Isoprenoids and Sterols. In *Handbook of Hydrocarbon and Lipid Microbiology*; Timmis, K.N., Ed.; Springer: Berlin/Heidelberg, Germany, 2010; pp. 127–131. [CrossRef]

18. Lichtenthaler, H.K. Evolution of Carotenoid and Isoprenoid Biosynthesis in Photosynthetic and Nonphotosynthetic Organisms. In Proceedings of the 16th International Plant Lipid Symposium, Budapest, Hungary, 1–4 June 2004.

19. Pulido, P.; Perello, C.; Rodriguez-Concepcion, M. New insights into plant isoprenoid metabolism. *Mol. Plant* 2012, 5, 964–967. [CrossRef] [PubMed]

20. Vranová, E.; Coman, D.; Gruissem, W. Network analysis of the MVA and MEP pathways for isoprenoid synthesis. *Annu. Rev. Plant Biol.* 2013, 64, 665–700. [CrossRef]

21. Weber, H. Fatty acid-derived signals in plants. *Trends Plant Sci.* 2002, 7, 217–224. [CrossRef]

22. Dewick, P.M. The biosynthesis of C5-C25 terpenoid compounds. *Nat. Prod. Rep.* 2002, 19, 181–222. [CrossRef]

23. Perreca, E.; Rohwer, J.; González-Cabanelas, D.; Loreto, E.; Schmidt, A.; Gershenzon, J.; Wright, L.P. Effect of Drought on the Methylerithritol 4-Phosphate (MEP) Pathway in the Isoprenoid Emitting Conifer *Picea glauca*. *Front. Plant Sci.* 2020, 11, 1535. [CrossRef]

24. Sonawane, P.D.; Pollier, J.; Panda, S.; Szymanski, J.; Massalha, H.; Yona, M.; Unger, T.; Malitsky, S.; Arendt, P.; Pauwels, L.; et al. Plant cholesterol biosynthetic pathway overlaps with phytosterol metabolism. *Nat. Plants.* 2016, 3, 16205. [CrossRef]

25. Cabianca, A.; Müller, I.; Pawlowski, K.; Dahlin, P. Changes in the Plant β-Sitosterol/Stigmasterol Ratio Caused by the Plant Parasitic Nematode *Meloidogyne incognita*. *Plants* 2021, 10, 292. [CrossRef]

26. Ohyama, K.; Suzuki, M.; Kikuchi, J.; Saito, K.; Muranaka, T. Dual biosynthetic pathways to phytosterol via cycloartenol and lanosterol in *Arabidopsis*. *Proc. Natl. Acad. Sci. USA* 2009, 106, 725–730. [CrossRef] [PubMed]

27. Grosso, C.; Valentião, P.; Ferreres, E.; Andrade, P.B. Alternative and efficient extraction methods for marine-derived compounds. *Mar. Drugs* 2015, 13, 3182–3230. [CrossRef] [PubMed]
28. Lagarda, M.J.; García-Llatas, G.; Farré, R. Analysis of phytosterols in foods. Rev. J. Pharm. Biomed. Anal. 2006, 41, 1486–1496. [CrossRef] [PubMed]

29. Gupta, A.; Naranival, M.; Kothari, V. Modern extraction methods for preparation of bioactive plant extracts. Int. J. Appl. Nat. Sci. 2012, 1, 8–26.

30. Smith, R.M. Before the injection-modern methods of sample preparation for separation techniques. Rev. J. Chromatogr. A 2003, 1000, 3–27. [CrossRef]

31. Uddin, M.S.; Ferdosh, S.; Haque Akanda, M.J.; Ghafoor, K.; Ah, R.; Ali, M.E.; Kamaruzzaman, B.Y.; Mb, F.; Shaarani, S.; Islam Sarker, M.Z. Techniques for the extraction of phytosterols and their benefits in human health: A review. Sep. Sci. Technol. 2018, 53, 2206–2223.

32. Pouloue, N.; Saajany, A.; Ravindran, A.; Chandran, A.; Priyadharshini, G.B.; Selvin, J.; Kiran, G.S. Anti-diabetic Potential of a Stigmasterol from the Seaweed Gelandium spinosum and Its Application in the Formulation of Nanoemulsion Conjugate for the Development of Functional Biscuits. Front. Nutr. 2021, 8, 694362. [CrossRef]

33. De Santi, I.I.; Pacheco, B.S.; Venzke, D.; Freitag, R.A.; de Almeida, L.S.; Colepicolo, P.; Pereira, C.M. Sterols in red macroalgae from the Adriatic Sea: Extraction and quantification by Gas Chromatography–Mass spectrometry. Polar Biol. 2021, 44, 987–995. [CrossRef]

34. Gololo, S.S.; Shai, L.J.; Sethoga, L.; Agyei, N.; Bassey, K.E.; Mogale, M.A. Isolation of a mixture of Phytosterol compounds from the n-Hexane extract of Jatropha lagarithinoides (Sond) collected from Zebediela sub-region in Limpopo province, South Africa. J. Chem. Pharm. Sci. 2016, 9, 3084–3087.

35. De Jong, D.L.; Timmermans, K.R.; de Winter, J.M.; Derksen, G.C. Effects of nutrient availability and light intensity on the sterol content of Saccharina latissima (Laminariales, Phaeophyceae). J. Appl. Phycol. 2013, 25, 1101–1113. [CrossRef]

36. Saini, R.K.; Mahomoodally, M.F.; Sadeer, N.B.; Keum, Y.S.; Rr Rengasamy, K. Characterization of nutritionally important lipophilic constituents from brown kelp Ecklonia radiata (C. Ag.). J. Agarbd. Food Chem. 2021, 340, 127897. [CrossRef]

37. Akbarry, P.; Liao, I.M.; Amninikhoei, Z.; Tabave, K.R.; Hobbi, M.; Erfanifar, E. Sterol and fatty acid profiles of three macroalgal species collected from the Chabahar coasts, southeastern Iran. Aquac. Int. 2021, 29, 155–165. [CrossRef]

38. Bermeira, L.M.; de Santi, I.I.; da Silva, C.C.; Venzke, D.; Colepicolo, P.; Vaucher, R.A.; Dos Santos, M.; de Pereira, C. Bioactivity and composition of lipophilic metabolites extracted from Antarctic macroalgae. Braz. J. Microbiol. 2021, 52, 1275–1285. [CrossRef] [PubMed]

39. Cvetković, D.; Dragović-Uzelac, V.; Dobrinčić, A.; Čož-Rakovac, R.; Balbino, S. The effect of solvent and extraction method on the recovery of lipid fraction from Adriatic Sea macroalgae. Algal Res. 2021, 56, 102291. [CrossRef]

40. Ahmed, S.A.; Rahman, A.A.; Elsayed, K.; Abd El-Mageed, H.R.; Mohamed, H.S.; Ahmed, S.A. Cytotoxic activity, molecular docking, pharmacokinetic properties and quantum mechanics calculations of the brown macroalga Cystoseira trinodis compounds. J. Biomol. Struct. Dyn. 2021, 39, 3855–3873. [CrossRef] [PubMed]

41. Xia, M.; Liu, C.; Gao, L.; Lu, Y. One-Step Preparative Separation of Phytosterols from Edible Brown Seaweed Sargassum hornieri by High-Speed Countercurrent Chromatography. Mar. Drugs 2019, 17, 691. [CrossRef]

42. Bogie, J.; Hoeks, C.; Schepers, M.; Tiane, A.; Cuypers, A.; Leijten, F.; Mulder, M. Dietary Sargassum fusiforme improves memory and reduces amyloid plaque load in an Alzheimer’s disease mouse model. Sci. Rep. 2019, 9, 1–16. [CrossRef]

43. Milović, S.; Stanković, I.; Nikolić, D.; Radović, J.; Kolundžić, M.; Nikolić, V.; Kundaković-Vasović, T. Chemical analysis of selected seaweeds and seagrass from the Adriatic Coast of Montenegro. Chem. Biodivers. 2019, 16, e1900327. [CrossRef]

44. Magura, J.; Moodley, R.; Jonnalagadda, S.B. Toxic metals (As and Pb) in Sargassum elegans Suhr (1840) and its bioactive compounds. Int. J. Environ. Health Res. 2019, 29, 266–275. [CrossRef]

45. Agatonovic-Kustrin, S.; Kustrin, E.; Gegechkori, V.; Morton, D.W. High-performance thin-layer chromatography hyphenated with microchemical and biochemical derivatizations in bioactivity profiling of marine species. Mar. Drugs 2019, 17, 148. [CrossRef]

46. Teixeira, T.R.; Santos, G.S.; Turatti, I.C.C.; Pazzi, M.H.; von Zeeska Kress, M.R.; Colepicolo, P.; Debonisi, H.M. Characterization of the lipid profile of Antarctic brown seaweeds and their endophytic fungi by gas chromatography–mass spectrometry (GC–MS). Polar Biol. 2019, 42, 1431–1444. [CrossRef]

47. Oh, J.H.; Choi, J.S.; Nam, T.J. Fucosterol from an edible brown alga Ecklonia stolonifera prevents soluble amyloid beta-induced cognitive dysfunction in aging rats. Mar. Drugs 2018, 16, 368. [CrossRef] [PubMed]

48. Ito, M.; Koba, K.; Hikihara, R.; Ishimaru, M.; Shibata, T.; Hatake, H.; Tanaka, R. Analysis of functional components and radical scavenging activity of 21 algae species collected from the Japanese coast. Food Chem. 2018, 255, 147–156. [CrossRef]

49. Terasaki, M.; Kawagoe, C.; Ito, A.; Kumon, H.; Narayan, B.; Hosokawa, M.; Miyashita, K. Spatial and seasonal variations in the biofunctional lipid substances (fucoxanthin and fucosterol) of the laboratory-grown edible Japanese seaweed (Sargassum horneri Turner) cultured in the open sea. Saudi J. Biol. Sci. 2017, 24, 1475–1482. [CrossRef]

50. Park, S.Y.; Hwang, E.; Shin, Y.K.; Lee, D.G.; Yang, J.E.; Park, J.H.; Yi, T.H. Immunostimulatory Effect of Enzyme-Modified Hizikia fusiforme in a Mouse Model In Vitro and Ex Vivo. Mar. Biotechnol. 2017, 19, 65–75. [CrossRef]

51. Kazłowska, K.; Lin, H.T.; Chang, S.H.; Tsai, G.J. In Vitro and In Vivo Anticancer Effects of Sterol Fraction from Red Algae Porphyra dentata. Evid.-Based Complementary Altern. Med. 2013, 2013, 493869. [CrossRef]

52. Xiao, H.X.; Zhi, Q.Y.; Gong, K.L. Preparation of phytosterols and phytol from edible marine algae by microwave-assisted extraction and high-speed counter-current chromatography. Sep. Purif. Technol 2013, 104, 284–289. [CrossRef]

53. Roiani, M.; Seyed, H.M.; Jinap, S.; Norhayati, H. Effect of extraction methods on yield, oxidative value, phytosterols and antioxidant content of cocoa butter. Int. Food Res. J. 2016, 23, 47–54.
54. Salkowski, F. The reaction of cholesterol with sulfuric acid. Arch. Dtsch. Ges. Physiol. 1872, 6, 207–222. [CrossRef]
55. Andrade, F.B.; Barbosa, M.; Matos, R.P.; Lopes, G.; Vinholes, J.; Mouga, T.; Valență, P. Valuable compounds in macroalgae extracts. Food Chem. 2013, 138, 1819–1829. [CrossRef]
56. Kendel, M.; Wielgosz-Collin, G.; Bertrand, S.; Roussakis, C.; Bourgougnon, N.; Bedoux, G. Lipid composition, fatty acids and sterols in the seaweeds Ulva armoricana, and Solieria chordalis from Brittany (France): An analysis from nutritional, chemotaxonomic, and antiprofihlerative activity perspectives. Mar. Drugs 2015, 13, 5606–5628. [CrossRef]
57. Bouzidi, N.; Viano, Y.; Porto, M.A.; Seridi, H.; Alliche, Z.; Daghbouche, Y.; Culioli, G.; Hattab, M. Sterols from the brown alga Cystoseira fonticulacea: Degradation of fucosterol into saringosterol epimers. Arab. J. Chem. 2019, 12, 1474–1478. [CrossRef]
58. Cabral, C.E.; Klein, M.R.S.T. Phytosterols in the treatment of hypercholesterolemia and prevention of cardiovascular diseases. Arq. Cardiol. 2017, 109, 475–482. [CrossRef] [PubMed]
59. Ikeda, I.; Tanaka, K.; Sugano, M.; Vahouny, G.V.; Gallo, L.L. Inhibition of cholesterol absorption in rats by plant sterols. J. Lipid Res. 1988, 29, 1573–1582. [CrossRef]
60. Zhen, X.H.; Quan, Y.C.; Jiang, H.Y.; Wen, Z.S.; Qu, Y.L.; Guan, L.P. Fucosterol, a sterol extracted from
61. Lee, Y.S.; Shin, K.H.; Kim, B.K.; Lee, S. Anti-diabetic activities of fucosterol from Pelvetia siliculosus. Arch. Pharmacal Res. 2004, 27, 1120–1122.
62. Phaniendra, A.; Jestadi, D.B.; Periyasamy, L. Free radicals: Properties, sources, targets, and their implication in various diseases. Indian J. Clin. Biochem. 2015, 30, 11–26. [CrossRef] [PubMed]
63. Ma, Q. Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 2013, 53, 401–426. [CrossRef] [PubMed]
64. Loboda, A.; Damulewicz, M.; Pyza, E.; Jozkowicz, A.; Dulak, J. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: An evolutionarily conserved mechanism. Cell. Mol. Life Sci. 2016, 73, 3221–3247. [CrossRef]
65. Jung, H.A.; Jin, S.E.; Ahn, B.R.; Lee, C.M.; Choi, J.S. Anti-inflammatory activity of edible brown alga Eisenia bicyclus and its constituents fucosterol and phlorotannins, show antioxidant activity and anticancer activity. Environ. Res. 2015, 137, 78–82. [CrossRef] [PubMed]
66. Loboda, A.; Damulewicz, M.; Pyza, E.; Jozkowicz, A.; Dulak, J. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: An evolutionarily conserved mechanism. Cell. Mol. Life Sci. 2016, 73, 3221–3247. [CrossRef]
67. Murugan, K.; Iyer, V.V. Antioxidant Activity and Gas Chromatographic-Mass Spectrometric Analysis of Extracts of the Marine Algae, Cauler papetlata and Padina gymnospora. Indian J. Pharm. Sci. 2014, 76, 548–552.
68. Fernando, I.; Jayawardena, T.U.; Sanjeeva, K.; Lee, H.G.; Nagahawatta, D.P.; Yang, H.W.; Kang, M.C.; Jeon, Y.J. Particulate Matter-Induced Inflammation/Oxidative Stress in Macrophages: Fucosterol from Padina boryana as a Potent Activator, Int. J. Mol. Sci. 2015, 16, 4015–4026. [CrossRef] [PubMed]
69. Wong, C.H.; Gan, S.Y.; Tan, S.C.; Gany, S.A.; Ying, T.; Gray, A.I.; Igoli, J.; Chan, E.W.L.; Phang, S.M. Fucosterol inhibits the cholinesterase activities and reduces the release of pro-inflammatory mediators in lipopolysaccharide and amyloid-induced microglial cells. J. Appl. Physiol. 2018, 30, 3261–3270. [CrossRef] [PubMed]
70. Murugan, K.; Iyer, V.V. Antioxidant Activity and Gas Chromatographic-Mass Spectrometric Analysis of Extracts of the Marine Algae, Cauler papetlata and Padina gymnospora. Indian J. Pharm. Sci. 2014, 76, 548–552.
71. Fernando, I.; Jayawardena, T.U.; Kim, H.S.; Vaas, A.; De Silva, H.; Nanayakkara, C.M.; Abeytunga, D.; Lee, W.; Ahn, G.; Lee, D.S.; et al. A keratinocyte and integrated fibroblast culture model for studying particulate matter-induced skin lesions and therapeutic intervention of fucosterol. Life Sci. 2019, 233, 116714. [CrossRef]
72. Fernando, I.; Jayawardena, T.U.; Kim, H.S.; Lee, W.W.; Vaas, A.; De Silva, H.; Abayaweerwa, G.S.; Nanayakkara, C.M.; Abeytunga, D.; Lee, D.S.; et al. Beijing urban particulate matter-induced injury and inflammation in human lung epithelial cells and the protective effects of fucosterol from Sargassum binerri (Sonner ex J. Agardh). Environ. Res. 2019, 172, 150–158. [CrossRef] [PubMed]
73. Choi, J.S.; Han, Y.R.; Byeon, J.S.; Chaung, S.Y.; Sohn, H.S.; Jung, H.A. Protective effect of fucosterol isolated from the edible brown alga Ecklonia stolonifera and Eisenia bicyclus, on tert-butyldihydroperoxide- and tamrin-induced HEPG2 cell injury. J. Pharm. Pharmacol. 2015, 67, 1170–1178. [CrossRef]
74. Jiang, H.; Li, J.; Chen, A.; Li, Y.; Xia, M.; Guo, P.; Yao, S.; Chen, S. Fucosterol exhibits selective anti-tumor antitumor activity against HeLa human cervical cell line by inducing mitochondrial mediated apoptosis, cell cycle migration inhibition and downregulation of m-TOR/PI3K/Akt signalling pathway. Oncol. Lett. 2018, 15, 3458–3463. [CrossRef]
75. Ko, W.; Lee, H.; Kim, N.; Jo, H.G.; Woo, E.R.; Lee, K.; Han, Y.S.; Park, S.R.; Ahn, G.; Cheong, S.H.; et al. The Anti-Oxidative and Anti-Neuroinflammatory Effects of Sargassum horneri by Heme Oxygenase-1 Induction in BV2 and HT22 Cells. Antioxidants 2021, 10, 859. [CrossRef]
76. Ibrahim, E.A.; Aly, H.F.; Baker, D.H.A.; Mahmoud, K.H.A.L.E.D.; El-Baz, F.K. Marine algal sterol hydrocarbon with anti-inflammatory, antioxidant, and anti-oxidant properties. Int. J. Pharma Bio Sci. 2016, 7, 392–398.
77. Santos, S.; Trindade, S.S.; Oliveira, C.; Parreira, P.; Rosa, D.; Duarte, M.F.; Ferreira, I.; Cruz, M.T.; Rego, A.M.; Abreu, M.H.; et al. Lipophilic Fraction of Cultivated Bifurcaria bifurcata, R. Ross: Detailed Composition and In Vitro Prospection of Current Challenging Bioactive Properties. Mar. Drugs 2017, 15, 340. [CrossRef]
78. Kavita, K.; Singh, V.K.; Jha, B. 24-Branched ∆S sterols from Laurencia papillosa red seaweed with antibacterial activity against human pathogenic bacteria. Microbiol. Res. 2014, 169, 301–306. [CrossRef] [PubMed]
80. Bakar, K.; Mohamad, H.; Tan, H.S.; Latip, J. Sterols compositions, antibacterial, and antifouling properties from two Malaysian seaweeds: Dictyota dichotoma and Sargassum granuliferum. J. Appl. Pharm. Sci. 2019, 9, 47–53. [CrossRef]

81. Rahelivao, M.P.; Gruner, M.; Andriamamantaonaina, H.; Bauer, I.; Knölker, H.J. Brown Algae (Phaeophyceae) from the Coast of Madagascar: Preliminary Bioactivity Studies and Isolation of Natural Products. Nat. Prod. Bioprospecting 2015, 5, 223–235. [CrossRef]

82. Elsayed, K.N.; Radwan, M.M.; Hassan, S.H.; Abdelhameed, M.S.; Ibraheem, I.B.; Ross, S.A. Phytochemical and biological studies on some Egyptian seaweeds. Nat. Prod. Commun. 2012, 7, 1209–1210. [CrossRef] [PubMed]

83. Wächter, G.A.; Franzblau, S.G.; Montenegro, G.; Hoffmann, J.J.; Maiese, W.M.; Timmermann, B.N. Inhibition of Mycobacterium tuberculosis growth by saringosterol from Lessonia nigrescens. J. Nat. Prod. 2001, 64, 1463–1464. [CrossRef]

84. Santoyo, S.; Plaza, M.; Jaime, L.; Ibáñez, E.; Reglero, G.; Señorans, J. Pressurized liquids as an alternative green process to extract antiplasmodial activity of fucosterol compound from brown seaweed, Sargassum linearifolium against malarial parasite Plasmodium falciparum. Nat. Prod. Res. 2018, 32, 1316–1319. [CrossRef] [PubMed]

85. Budiman, A.; Rusnawan, D.W.; Yuliana, A. Antibacterial activity of Piper betle L. extract in cream dosage forms against Staphylococcus aureus and Propionibacterium acnes. J. Pharm. Sci. Res. 2018, 10, 493–496.

86. Ferrero-Miliani, L.; Nielsen, O.; Andersen, P.; Girardin, S. Chronic inflammation: Importance of NOD2 and NALP3 in interleukin-1β generation. Clin. Exp. Immunol. 2007, 147, 227–235. [CrossRef]

87. Muller, W.A. Getting leukocytes to the site of inflammation. Vet. Pathol. 2015, 50, 7–22. [CrossRef]

88. Zhang, J.M.; An, J. Cytokines, inflammation, and pain. Vet. Pathol. 2007, 44, 7–22. [CrossRef] [PubMed]

89. Clark, M.; Kroger, C.J.; Tisch, R.M. Type 1 Diabetes: A Chronic Anti-Self-Inflammatory Response. Nat. Med. 2004, 18, 27–37. [CrossRef] [PubMed]

90. Barbalace, M.C.; Malaguti, M.; Giusti, L.; Lucacchini, A.; Hrelia, S.; Angeloni, C. Anti-inflammatory activities of marine algae in neurodegenerative diseases. Int. J. Mol. Sci. 2019, 20, 3061. [CrossRef]

91. Jin, D.Q.; Lim, C.S.; Sung, J.Y.; Choi, H.G.; Ha, I.; Han, J.S. Ulva conglobata, a marine algae, has neuroprotective and anti-inflammatory effects in murine hippocampal and microglial cells. Neurosci. Lett. 2006, 402, 154–158. [CrossRef] [PubMed]

92. Bayarri, J.M.; An, J. Cytokines, inflammation, and pain. Int. Anesthesiol. Clin. 2007, 45, 27–37. [CrossRef]

93. Stabili, L.; Fraschetti, S.; Acquaviva, M.I.; Cavallio, R.A.; De Pascali, S.A.; Fanizzi, F.P.; Gerardi, C.; Narracci, M.; Rizzo, L. The Potential Exploitation of the Mediterranean Invasive Alga Caulerpa cylindracea: Can the Invasion Be Transformed into a Gain? Mar. Drugs 2016, 14, 210. [CrossRef]

94. Sun, Z.; Mohamed, M.A.A.; Park, S.Y.; Yi, T.H. Fucosterol protects cobalt chloride induced inflammation by the inhibition of hypoxia-inducible factor through PI3K/Akt pathway. Int. Immunopharmacol. 2015, 29, 642–647. [CrossRef]

95. Li, Y.; Li, X.; Liu, G.; Sun, R.; Wang, L.; Wang, J.; Wang, H. Fucosterol attenuates lipopolysaccharide-induced acute lung injury in mice. J. Surg. Res. 2015, 195, 515–521. [CrossRef]

96. Lawrence, T. The nuclear factor NF-κB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 2009, 1, a001651. [CrossRef]

97. Johnson, G.V.; Bailey, C.D. The p38 MAP kinase signaling pathway in Alzheimer’s disease. Exp. Neurol. 2003, 183, 263–268. [CrossRef]

98. Senthil, S.; Neumann, M.; Vieth, M.; Roessner, A.; Malfertheiner, P.; Naumann, M. Inhibition of p38 MAP kinase- and RICK/NF-κB-signaling suppresses inflammatory bowel disease. FASEB J. 2004, 18, 1550–1552. [CrossRef]

99. Schett, G.; Zwerina, J.; Firestein, G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann. Rheum. Dis. 2008, 67, 909–916. [CrossRef] [PubMed]

100. Zarubin, T.; Jiahuai, H.A.N. Activation and signaling of the p38 MAP kinase pathway. Cell Res. 2005, 15, 11–18. [CrossRef] [PubMed]
108. Yoo, M.S.; Shin, J.S.; Choi, H.E.; Cho, Y.W.; Bang, M.H.; Baek, N.I.; Lee, K.T. Fucosterol isolated from Undaria pinnatifida inhibits lipopolysaccharide-induced production of nitric oxide and pro-inflammatory cytokines via the inactivation of nuclear factor-κB and p38 mitogen-activated protein kinase in RAW264.7 macrophages. *Food Chem.* **2012**, *135*, 967–975. [CrossRef]

109. O’Brien, R.J.; Wong, P.C. Amyloid precursor protein processing and Alzheimer’s disease. *Annu. Rev. Neurosci.* **2011**, *34*, 185–204. [CrossRef]

110. Khairi, G.; Dolatshahi, M.; Rahmani, F.; Rezaei, N. Role of p38/MAPKs in Alzheimer’s disease: Implications for amyloid beta toxicity targeted therapy. *Rev. Neurosci.* **2019**, *30*, 9–30. [CrossRef] [PubMed]

111. Mandlekar-Colucci, S.; Landreth, G.E. Microglia and inflammation in Alzheimer’s disease. *CNS Neurol. Disord.-Drug Targets* **2010**, *9*, 156–167. [CrossRef]

112. Heneka, M.T.; Carson, M.J.; El Khoury, J.; Landreth, G.E.; Brosseron, F.; Feinstein, D.L.; Jacobs, A.H.; Wyss-Coray, T.; Vitorica, J.; Ransohoff, R.M.; et al. Neuroinflammation in Alzheimer’s disease. *Lancet Neurol.* **2015**, *14*, 388–405. [CrossRef]

113. Jiang, H.A.; Ali, M.Y.; Choi, R.J.; Jeong, H.O.; Chung, H.Y.; Choi, J.S. Kinetics and molecular docking studies of fucosterol and fucosan, BACE1 inhibitors from brown algae Undaria pinnatifida and Ecklonia stolonifera. *Food Chem. Toxicol.* **2016**, *89*, 104–111. [CrossRef]

114. Mandlekar, S.; Jiang, Q.; Lee, C.D.; Koenigsknecht-Talbou, J.; Holtzman, D.M.; Landreth, G.E. Microglia mediate the clearance of soluble Aβ through fluid phase macropinocytosis. *J. Neurosci.* **2009**, *29*, 4252–4262. [CrossRef]

115. Alghazwi, M.; Smid, S.; Musgrave, I.; Zhang, W. In vitro studies of the neuroprotective activities of astaxanthin and fucoxanthin against amyloid beta (Aβ1–42) toxicity and aggregation. *Neurochem. Int.* **2019**, *124*, 215–224. [CrossRef]

116. Jiang, L.; Zhao, X.; Xu, J.; Li, C.; Yu, Y.; Wang, W.; Zhu, L. The protective effect of dietary phytosterols on cancer risk: A systematic meta-analysis. *J. Oncol.* **2019**, *2019*, 7497518. [CrossRef]

117. Li, K.; Yuan, D.; Yan, R.; Meng, L.; Zhang, Y.; Zhu, K. Stigmasterol exhibits potent antitumor effects in human gastric cancer cells mediated via inhibition of cell migration, cell cycle arrest, mitochondrial mediated apoptosis and inhibition of JAK/STAT signaling pathway. *J. BUON 2018*, *23*, 1420–1425. [PubMed]

118. Ali, H.; Dixit, S.; Ali, D.; Alqahtani, S.M.; Alkahtani, S.; Alarifi, S. Isolation and evaluation of anticancer efficacy of stigmasterol in human breast and colon cancer cell lines. *Sci. Rep.* **2016**, *7*, 156–167. [CrossRef]

119. Zhao, H.; Zhang, X.; Wang, M.; Lin, Y.; Zhou, S. Stigmasterol Simultaneously Induces Apoptosis and Protective Autophagy by Inhibiting Akt/mTOR Pathway in Gastric Cancer Cells. *Front. Oncol.* **2021**, *11*, 43. [CrossRef]

120. Pattingre, S.; Espert, L.; Biard-Piechaczyk, M.; Codogno, P. Regulation of macroautophagy by mTOR and Beclin 1 complexes. *Autophagosome and Phagosome; Humana Press: Totowa, NJ, USA, 2008, pp.* 77–88.

121. Nishida, N.; Yano, H.; Nishida, T.; Kamura, T.; Kojiro, M. Angiogenesis in cancer. *Rev. Neurosci.* **2011**, *22*, 156–167. [CrossRef]

122. Ikarashi, N.; Ono, T.; Hoshino, M.; Toda, T.; Yazawa, Y.; Sugiyama, K. Mechanistic Analysis of Bladder Cancer Suppression by Brassicasterol in a Rat Model of N-butyl-N-(4-Hydroxybutyl) Nitrosamine-Induced Bladder Cancer. In *Traditional & Kampo Medicine*; Humana Press: Totowa, NJ, USA, 2008; pp. 219–228. [CrossRef]

123. Li, K.; Yuan, D.; Yan, R.; Meng, L.; Zhang, Y.; Zhu, K. Stigmasterol exhibits potent antitumor effects in human gastric cancer cells mediated via inhibition of cell migration, cell cycle arrest, mitochondrial mediated apoptosis and inhibition of JAK/STAT signaling pathway. *J. BUON 2018*, *23*, 1420–1425. [PubMed]

124. Thanan, R.; Murata, M.; Ma, N.; Hammm, O.; Wishai, M.; El Leithy, T.; Kawanishi, S. Nuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancer. *Mediat. Inflamm.* **2012**, *2012*, 165879. [CrossRef] [PubMed]

125. Ikarker, N.; Ono, T.; Hoshino, M.; Toda, T.; Yazawa, Y.; Sugiyama, K. Mechanistic Analysis of Bladder Cancer Suppression by Brassicasterol in a Rat Model of N-butyl-N-(4-Hydroxybutyl) Nitrosamine-Induced Bladder Cancer. In *Traditional & Kampo Medicine*; Humana Press: Totowa, NJ, USA, 2008; pp. 219–228. [CrossRef]

126. Baptista, A.A.; Ignacimuthu, S.; Paulraj, G.M.; Al Numair, K.S. Chemopreventive potential of β-sitosterol in experimental colon cancer model-an in vitro and in vivo study. *BMC Complementary Altern. Med.* **2010**, *10*, 24. [CrossRef] [PubMed]

127. Bhattacharyya, S.; Bose, S.; Bhattacharyya, S.; Datta, B. β-sitosterol induces G1 arrest and causes depolarization of mitochondrial membrane potential in breast carcinoma MDA-MB-231 cells. *BMC Complementary Altern. Med.* **2013**, *13*, 280. [CrossRef] [PubMed]

128. Rajavel, T.; Mohankumar, R.; Archunan, G.; Ruckmani, K.; Devi, K.P. Beta sitosterol and Daucosterol (phytosterols identified in Grewia tiliaefolia) perturbs cell cycle and induces apoptotic cell death in A549 cells. *Sci. Rep.* **2017**, *7*, 1–15. [CrossRef] [PubMed]

129. Li, Y.B.; Han, L.B.; Wang, H.Y.; Zhang, J.; Sun, S.T.; Feng, D.Q.; Xia, G.X. The thioredoxin GbnRx1 plays a crucial role in homeostasis of apoplastic reactive oxygen species in response to Verticillium dahliae infection in cotton. *Plant Physiol.* **2016**, *170*, 2392–2406. [CrossRef] [PubMed]

130. Rajavel, T.; Packiyaraj, P.; Suryanarayanan, V.; Singh, S.K.; Ruckmani, K.; Devi, K.P. β-Sitosterol targets Trx/Trx1 reductase to induce apoptosis in A549 cells via ROS mediated mitochondrial dysregulation and p53 activation. *Sci. Rep.* **2018**, *8*, 1–15. [CrossRef]

131. Mofeed, J.; Deyab, M.; Sabry, A.E.N.; Ward, F. In Vitro Anticancer Activity of Five Marine Seaweeds Extract from Egypt Against Human Breast and Colon Cancer Cell Lines. *Res. Sq.* **2021**. [CrossRef]
161. Feng, S.; Belwal, T.; Li, L.; Limwachiranon, J.; Liu, X.; Luo, Z. Phytosterols and their derivatives: Potential health-promoting uses against lipid metabolism and associated diseases, mechanism, and safety issues. *Compr. Rev. Food Sci. Food Saf.* 2020, 19, 1243–1267. [CrossRef] [PubMed]

162. O’Callaghan, Y.; Kenny, O.; O’Connell, N.M.; Maguire, A.R.; McCarthy, F.O.; O’Brien, N.M. Synthesis and assessment of the relative toxicity of the oxidised derivatives of campesterol and dihydrobrassicasterol in U937 and HepG2 cells. *Biochimie* 2013, 95, 496–503. [CrossRef]